Abstract It has been suggested that normalization of Study of 134 haemodialysis patients found a significant improvement in all quality-of-life parameters when haemoglobin with epoetin in anaemic chronic renal failure (CRF ) patients might result in even greater haemoglobin was increased to a mean of 12.5 g/dl.
(9.0-12.0 g/dl ) and those in whom haemoglobin was normalized (13.5-16.0 g/dl ). The Canadian Numerous trials show that partial correction of anaeMulticentre Trial included 159 haemodialysis patients mia with epoetin in haemodialysis patients with chronic with asymptomatic left ventricular (LV ) dysfunction. renal failure (CRF ) is associated not only with relief In patients with a normal LV cavity volume at enrol-of anaemic symptoms, but also with partial regression ment, the change in LV cavity volume at 48 weeks was of left ventricular hypertrophy (LVH ) and improvesignificantly greater in the control group (target hae-ments in quality of life (J. F. E. Mann, this volume). moglobin 9.5-10.5 g/dl ) than in the intervention group However, it is not yet clear whether full correction of (target haemoglobin 13.0-14.0 g/dl ). The Normal anaemia will have further beneficial effects. Hematocrit Cardiac Trial in the US included 1233 Moreover, despite more than a decade of clinical haemodialysis patients with clinically evident ischaemic experience with epoetin, the optimal target haemoheart disease or congestive heart failure. The trial was globin must still be defined. The National Kidney stopped in 1996 after an interim analysis showed Foundation-Dialysis Outcomes Quality Initiative increased mortality in the intervention group (target (NKF-DOQITM ) guidelines currently recommend a haematocrit 42%) compared with the control group target haemoglobin of 11-12 g/dl [1] . This recom-(target haematocrit 30%). The higher haematocrit mendation was based on a review of the literature values themselves, however, did not appear to be available at the time, which found an association responsible for the differences in mortality, as the between increased morbidity and mortality and a haemortality rates within each group decreased with moglobin of ∏10 g/dl. However, as preliminary data increasing haematocrit. Nonetheless, until evidence is from more recent trials show beneficial effects from available from other trials demonstrating a benefit of increasing haemoglobin to normal, the NKF-DOQI normalizing haemoglobin, it has been recommended guidelines acknowledge that a higher target haematothat a target haematocrit value of 42% be avoided in crit/haemoglobin may ultimately prove to be more haemodialysis patients with clinically evident ischaemic appropriate in CRF patients. heart disease or congestive heart failure. Further studThere are reasons for supposing that normalizing ies are also required to determine whether increasing haemoglobin may be beneficial. First, there is an haemoglobin to normal may prove to be beneficial in intuitive belief that hormone replacement therapyother patient groups. The Spanish Quality of Life whether it be for diabetes or renal anaemia-should strive to achieve a normal physiological value. Correspondence and offprint requests to: Professor Claude Jacobs, Haemoglobin concentrations at the currently recomService de Néphrologie, Hô pital de la Pitié-Salpêtrière, 83 Boulevard de l' Hô pital, 75013 Paris, France. mended 11-12 g/dl are considerably less than the lower limit of the normal range for males and post-clotting of dialysers and heparin dose were also menopausal females (13.5-17.5 g/dl ) and less than or monitored. at the lower limit of normal for pre-menopausal
To evaluate further potential benefits and adverse females (12.0-16.0 g/dl ). Second, indirect evidence effects, several substudies were performed. These studfrom prospective and retrospective studies shows that ies included echocardiography, rheology, renal functhe risk of LV dilatation, heart failure and premature tion (in pre-dialysis patients), dialysis adequacy, death increases as the anaemia of CRF worsens [2] [3] [4] [5] . coagulation parameters, iron dose, iron supplemThese findings logically suggest that the more effec-entation and serum transferrin receptor, and the results tively anaemia is corrected, the greater the potential of renal transplantation of all transplanted patients. benefits in terms of symptom relief, regression and
In view of the early termination of the Normal prevention of LVH, and improvements in quality of Hematocrit Cardiac Trial in the US (see below), an life. It might reasonably be predicted that mortality interim analysis of cardiovascular adverse events was would also be reduced.
performed on two occasions during the present study. There is, however, a legitimate concern that increas-These analyses found no differences between the patient ing haemoglobin to normal might also be associated groups with normal and subnormal haemoglobin with unknown risks. Evidence from randomized, con-values with respect to safety. trolled trials in which adverse events can be assessed Although the study data had not been analysed at properly is therefore needed before the optimal target the time of the symposium, the subjective impression haemoglobin for patients receiving epoetin treatment was that a normal haemoglobin value would be of can be determined.
great benefit, particularly for pre-dialysis patients. Publication of four recent prospective studies of Publication of the full trial results is expected in 1999. CRF patients will hopefully provide such evidence. These studies investigated the effects of normalizing haemoglobin with epoetin on cardiovascular outcomes and quality of life. The four study designs and preliminary trial results were reported and discussed during a
Canadian Multicentre Trial
workshop at the 2nd European Epoetin Symposium, Optimizing Anaemia Therapy in CRF. This article sum-
The Canadian Multicentre Trial investigated whether marizes the information on these trials that was available at the time of the workshop, as well as the normalization of anaemia with epoetin alfa could conclusions reached by the workshop participants improve LV geometry and quality of life in 159 anaemic based on the data presented.
haemodialysis patients with asymptomatic LV disease. Patients from both sets were randomized to either: randomized, controlled study of the effects of elevating (i) an intervention group (epoetin alfa dose titrated haemoglobin from subnormal to normal values. upwards to achieve a target haemoglobin of Various efficacy and safety parameters were investi-13.0-14.0 g/dl within 6 months, and maintenance of gated, with an emphasis on cardiovascular function this target up to 48 weeks from study entry); or (ii) a and quality of life. A total of 416 haemodialysis, control group (epoetin alfa given to maintain continuous ambulatory peritoneal dialysis, and pre-a haemoglobin of 9.5-10.5 g/dl ). dialysis patients aged 18-80 years were included in the Outcome measures were change in LV volume and trial, which was conducted in Sweden, Norway, LV mass. Both intention-to-treat and efficacy analFinland and Iceland. The last patient completed the yses were conducted, comparing echocardiograms study in February 1998. performed at baseline with those taken 40 weeks after Patients were randomized to treatment with epoetin the start of the study. alfa, with the intention of either: (i) maintaining haeBased on the preliminary trial results, it was conmoglobin within the subnormal range (9.0-12.0 g/dl );
cluded that, compared with partial correction of anaeor (ii) increasing haemoglobin to normal (13.5-mia, normalization of haemoglobin with epoetin may 16.0 g/dl ), with the aim of increasing the haemoglobin prevent progressive LV dilation in haemodialysis by at least 25%. Following a titration period (usually patients with a normal LV volume. However, it does 3-6 months), patients were kept at a steady-state not induce regression of concentric LVH or of LV haemoglobin for 12 months. dilatation in patients with pre-existing LV dilatation. Physical, biochemical and haematological paramAs these results suggest that the adverse effects of eters, quality of life, iron status, chest X-ray, renal anaemia on the heart can be prevented, but not function, exercise capacity, epoetin alfa and iron reversed, early normalization of haemoglobin may dosing, hospitalizations and adverse events were monitored in all patients. In the haemodialysis patients, prove to be the most beneficial strategy.
domized to the normal haematocrit group, and was the US was to examine the risks and benefits of associated with an increased risk of death. Whether normalizing haematocrit in haemodialysis patients with the administration of i.v. iron supplements could be cardiac disease. A total of 1233 haemodialysis patients linked to an increased risk of complications, however, with clinically evident congestive heart failure or isis a question that remains unresolved [8] . chaemic heart disease were included in the trial [6 ] . Patients were randomized to one of two groups: a normal haematocrit group (n=618), in which patients Spanish Quality of Life Study received doses of epoetin sufficient to achieve and maintain a haematocrit of 42±3%, and a low haematoThis study was designed to measure the effects of crit group (n=615), in which patients received doses increasing haematocrit with epoetin on quality of life. of epoetin sufficient to maintain a haematocrit of
The aim was to increase haematocrit by~5 percentage 30±3%. The primary end point was time to death or points. Quality of life was measured before the study, a first non-fatal myocardial infarction.
and at 3 and 6 months, using the Karnofsky Scale and The study was stopped prematurely after an interim the Sickness Impact Profile. The study included only analysis at 29 months showed 183 deaths and 19 first stable haemodialysis patients under 65 years of age, non-fatal myocardial infarctions in patients randomwho were already receiving epoetin and who had ized to the normal haematocrit group vs 150 deaths haematocrits of 30-35%. Diabetic patients as well as and 14 first non-fatal myocardial infarctions in those patients with a history of cerebrovascular accident, randomized to the low haematocrit group (risk ratio seizures, severe arterial hypertension, vascular access normal vs low haematocrit: 1.3; 95% repeated confidmalfunction and severe co-morbidity were excluded. ence interval: 0.9-1.9). Although the difference in A total of 134 patients were enrolled, 115 of whom event-free survival between the two groups did not completed the 6 months of follow-up. Ten of the 134 reach the pre-specified statistical stopping boundary, enrolled patients were excluded from the study, nine the study was halted because of safety concerns and (6%) because of thrombosis of the vascular access and because it was considered that an attempt to prove one because of uncontrolled arterial hypertension. benefit for the higher haematocrit group would be There were no deaths during the study. futile.
The mean haematocrit increase in the 115 patients The differences in outcomes in the two groups could who completed the study was 7.8. The mean haematonot be explained by 11 prespecified baseline charactercrit achieved was 39±2.1, equivalent to a mean haemoistics, because adjustment for these factors in a Cox globin of 12.5±1 g/dl. regression analysis did not change the risk ratio for All tests used demonstrated a significant improvepatients randomized to the normal-vs the lowment in quality of life. The global score of the Sickness haematocrit group. Although it remains unclear why Impact Profile decreased from a mean of 7.8 to 5.7 (P patients randomized to the normal-haematocrit group <0.0001) (the lower the score, the better the quality fared less well than those assigned to the lowof life). The physical dimension score decreased from haematocrit group, it is important to note that the a mean of 5.3 to 3.9 (P <0.005) and the psychosocial mortality rates decreased with increasing haematocrit dimension score decreased from 8.8 to 6.1 (P <0.0001) in each group. When 'group assignment' was replaced ( Figure 1 ). in the analysis by 'average haematocrit', the risk ratio was 0.7 (95% confidence interval: 0.6-0.8, P<0.001), indicating a 30% reduction in the risk of death or myocardial infarction for a 10 point increase in haematocrit. This suggests that the increased mortality in patients randomized to the normal haematocrit group was not due to haematocrit itself. The causes of death in the two groups were similar. Post-hoc analyses suggest that two other factors may have contributed to the disparate outcomes in this trial. First, patients randomized to the normal haematocrit group showed a decline in the adequacy of dialysis during the study ( lower Kt/V values), whereas Kt/V values increased *Although the full results of the Normal Hematocrit Cardiac Trial were not available at the time of the workshop, they were published four months later [6 ] and the text reviewing this trial has been updated accordingly. It is important to note, however, that there is Fig. 1 . Spanish Quality of Life Study: change in Sickness Impact wide debate regarding interpretation of the methodology and statistical analyses used (for a discussion of the limitations and criticisms Profile quality-of-life indicators from baseline, in patients whose mean haemoglobin was increased to 12.5 g/dl. of this trial, see [7] ).
It was concluded that quality of life improved sig-cardiovascular effects. However, the Scandinavian Multicentre Trial initially included fewer patients with nificantly when haematocrit was increased, despite the fact that the patients were already stable on epoetin severe cardiac disease and, in response to early termination of the Normal Haematocrit Cardiac Trial, any prior to the study. The incidence of adverse effects in this study was negligible, but it is important to note such patients were withdrawn from the study at the first interim analysis. The Canadian Multicentre Trial that patients were screened rigorously to exclude diabetic patients and those with severe hypertension or excluded patients with cardiac symptoms from the outset, though all had evidence of asymptomatic LV other severe co-morbidity. Although the investigators acknowledged that individualization of target haem-disease.
It is possible, therefore, that the difference between atocrit is necessary, they suggested that it should be as close to normal as possible in patients without severe the study populations in these three trials might explain the differences in the trial results with regard to safety. co-morbidity.
Should haemoglobin be normalized? Conclusions
Full correction is often advised in, for example, irondeficiency anaemia, vitamin B 12 -deficiency anaemia On the basis of the Normal Hematocrit Cardiac Trial and thalassaemia. In addition, in hormone-deficient findings, and pending the results of other trials, the states such as Addison's disease, hypothyroidism, oes-workshop suggested that normalization of haemotrogen deficiency and diabetes mellitus, the aim of globin in patients with CRF be avoided in the presence hormone replacement therapy is to emulate the physio-of documented ischaemic heart disease or congestive logical effects of normal hormone concentrations. Yet, heart failure. It is hoped that publication after peerfull correction of the anaemia of CRF, which is also a review of the full results of the Scandinavian, Canadian hormone-deficient state, is still a controversial issue.
and Spanish multicentre trials will help to quantify as The available evidence indicates that quality of life, well as qualify the potential benefits and risks of exercise capacity and cardiac output are likely to normalizing haemoglobin in CRF patients. improve as haemoglobin approaches normal. The preThere was agreement among the workshop particiliminary data from the Canadian Multicentre Trial pants that increasing haemoglobin to normal may be suggest that normalizing anaemia with epoetin alfa beneficial in selected groups of CRF patients. Further prevents progressive LV dilatation in patients who studies, with clear and robust end points, are required have not yet developed this adverse cardiac effect as a not only to identify more precisely which patients result of prolonged anaemia. Thus, early normalization would benefit most, but also to explore the impact of of haemoglobin, probably starting in the pre-dialysis early normalization of haemoglobin, with a view to period, would seem to be a logical strategy for pro-preventing the long-term complications of renal tecting the heart. anaemia. Normalization of haemoglobin does not appear to have any negative impact on blood pressure stability, nor does it seem to increase the likelihood of thrombotic events [6,9-11]. Although an increase in the need for antihypertensive medication is seen in~20% of References patients receiving epoetin therapy for the anaemia of There was no evidence of increased mortality or
